{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:40:30Z","timestamp":1790797230425,"version":"4.1.0"},"reference-count":312,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.3233\/jhd-170273","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T15:51:50Z","timestamp":1522165910000},"page":"109-135","source":"Crossref","is-referenced-by-count":51,"title":["A Critical Evaluation of Wet Biomarkers for Huntington\u2019s Disease: Current Status and Ways Forward"],"prefix":"10.1177","volume":"7","author":[{"given":"Edina","family":"Silajd\u017ei\u0107","sequence":"first","affiliation":[{"name":"Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bj\u00f6rkqvist","sequence":"additional","affiliation":[{"name":"Department of Experimental Medical Science, Brain Disease Biomarker Unit, Wallenberg Neuroscience Center, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"6","key":"10.3233\/JHD-170273_ref1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.3233\/JHD-170273_ref2","doi-asserted-by":"crossref","first-page":"c3109","DOI":"10.1136\/bmj.c3109","article-title":"Huntington\u2019s disease","volume":"340","author":"Novak","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"10.3233\/JHD-170273_ref3","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.3233\/JHD-170273_ref4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/01.WNL.0000086373.32347.16","article-title":"Huntington\u2019s disease: Clinical correlates of disability and progression","volume":"61","author":"Mahant","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.3233\/JHD-170273_ref5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","article-title":"Formation of polyglutamine inclusions in non-CNS tissue","volume":"8","author":"Sathasivam","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.3233\/JHD-170273_ref6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: Widespread pathology in Huntington\u2019s disease","volume":"8","author":"van der Burg","year":"2009","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.3233\/JHD-170273_ref7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","article-title":"Treating the whole body in Huntington\u2019s disease","volume":"14","author":"Carroll","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/JHD-170273_ref8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JHD-170273_ref9","unstructured":"BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD). 2016."},{"issue":"6","key":"10.3233\/JHD-170273_ref10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00005072-199806000-00010","article-title":"A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: Current status, relevance to drug discovery, and recommendations for future research","volume":"57","author":"Trojanowski","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JHD-170273_ref11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-62703-411-1_2","article-title":"Huntington\u2019s disease and cell therapies: Past, present, and future","volume":"1010","author":"Antoniades","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.3233\/JHD-170273_ref12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00004850-200403000-00001","article-title":"Huntington\u2019s disease: Present treatments and future therapeutic modalities","volume":"19","author":"Bonelli","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.3233\/JHD-170273_ref13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/14728210902918299","article-title":"Emerging drug therapies in Huntington\u2019s disease","volume":"14","author":"Mason","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"10.3233\/JHD-170273_ref14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.parkreldis.2014.12.013","article-title":"Update on Huntington\u2019s disease: Advances in care and emerging therapeutic options","volume":"21","author":"Zielonka","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"10.3233\/JHD-170273_ref15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: Analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"issue":"31","key":"10.3233\/JHD-170273_ref16","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1073\/pnas.0504921102","article-title":"Genome-wide expression profiling of human blood reveals biomarkers for Huntington\u2019s disease","volume":"102","author":"Borovecki","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.3233\/JHD-170273_ref17","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/mds.23337","article-title":"Challenges assessing clinical endpoints in early Huntington disease","volume":"25","author":"Paulsen","year":"2010","journal-title":"Mov Disord"},{"issue":"6","key":"10.3233\/JHD-170273_ref20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/1073858405280639","article-title":"The ubiquitin-proteasome system in Huntington\u2019s disease","volume":"11","author":"Valera","year":"2005","journal-title":"Neuroscientist"},{"issue":"4","key":"10.3233\/JHD-170273_ref21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pneurobio.2007.03.004","article-title":"Transcriptional signatures in Huntington\u2019s disease","volume":"83","author":"Cha","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.3233\/JHD-170273_ref22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1196\/annals.1427.008","article-title":"Evidence of oxidant damage in Huntington\u2019s disease: Translational strategies using antioxidants","volume":"1147","author":"Stack","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JHD-170273_ref23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1196\/annals.1427.018","article-title":"Mitochondria and Huntington\u2019s disease pathogenesis: Insight from genetic and chemical models","volume":"1147","author":"Browne","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.3233\/JHD-170273_ref24","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J Exp Med"},{"issue":"8","key":"10.3233\/JHD-170273_ref25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00702-010-0430-7","article-title":"Neuroinflammation in Huntington\u2019s disease","volume":"117","author":"Moller","year":"2010","journal-title":"J Neural Transm"},{"issue":"Pt 7","key":"10.3233\/JHD-170273_ref26","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington\u2019s disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"issue":"2","key":"10.3233\/JHD-170273_ref27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","article-title":"Early and progressive accumulation of reactive microglia in the Huntington disease brain","volume":"60","author":"Sapp","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"10.3233\/JHD-170273_ref28","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","article-title":"Microglial activation correlates with severity in Huntington disease: A clinical and PET study","volume":"66","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.3233\/JHD-170273_ref29","doi-asserted-by":"crossref","first-page":"541259","DOI":"10.1155\/2013\/541259","article-title":"The role of the immune system in Huntington\u2019s disease","volume":"2013","author":"Ellrichmann","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"7","key":"10.3233\/JHD-170273_ref30","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J Proteome Res"},{"issue":"7","key":"10.3233\/JHD-170273_ref31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1179\/1743132812Y.0000000073","article-title":"Oxidative stress and inflammation biomarkers in the blood of patients with Huntington\u2019s disease","volume":"34","author":"Sanchez-Lopez","year":"2012","journal-title":"Neurol Res"},{"key":"10.3233\/JHD-170273_ref32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington\u2019s disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav Immun"},{"issue":"4","key":"10.3233\/JHD-170273_ref33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JHD-160213","article-title":"Plasma cytokine levels in relation to neuropsychiatric symptoms and cognitive dysfunction in Huntington\u2019s disease","volume":"5","author":"Bouwens","year":"2016","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-170273_ref34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fphys.2014.00231","article-title":"Metabolic and hormonal signatures in pre-manifest and manifest Huntington\u2019s disease patients","volume":"5","author":"Wang","year":"2014","journal-title":"Front Physiol"},{"key":"10.3233\/JHD-170273_ref35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","article-title":"Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington\u2019s disease gene carriers","volume":"83","author":"Politis","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"7","key":"10.3233\/JHD-170273_ref36","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1371\/journal.pone.0000647","article-title":"Early energy deficit in Huntington disease: Identification of a plasma biomarker traceable during disease progression","volume":"2","author":"Mochel","year":"2007","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JHD-170273_ref37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JHD-130049","article-title":"A critical evaluation of inflammatory markers in Huntington\u2019s Disease plasma","volume":"2","author":"Silajdzic","year":"2013","journal-title":"J Huntingtons Dis"},{"issue":"4","key":"10.3233\/JHD-170273_ref38","first-page":"779","article-title":"Huntington\u2019 disease\u2013imbalance of amino acid levels in plasma of patients and mutation carriers","volume":"20","author":"Gruber","year":"2013","journal-title":"Ann Agric Environ Med"},{"issue":"8","key":"10.3233\/JHD-170273_ref39","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.euroneuro.2014.05.004","article-title":"Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington\u2019s disease","volume":"24","author":"Bouwens","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10.3233\/JHD-170273_ref40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington\u2019s disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J Neurochem"},{"issue":"10","key":"10.3233\/JHD-170273_ref41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1515\/CCLM.1998.132","article-title":"Activated immune system in patients with Huntington\u2019s disease","volume":"36","author":"Leblhuber","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"10.3233\/JHD-170273_ref42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4615-4709-9_19","article-title":"Degradation of tryptophan in neurodegenerative disorders","volume":"467","author":"Widner","year":"1999","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.3233\/JHD-170273_ref43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1471-4159.2006.03807.x","article-title":"Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington\u2019s disease or chronic brain injury","volume":"97","author":"Christofides","year":"2006","journal-title":"J Neurochem"},{"issue":"2","key":"10.3233\/JHD-170273_ref44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.expneurol.2007.12.026","article-title":"The metabolic profile of early Huntington\u2019s disease\u2013a combined human and transgenic mouse study","volume":"210","author":"Goodman","year":"2008","journal-title":"Exp Neurol"},{"issue":"9","key":"10.3233\/JHD-170273_ref45","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1212\/01.WNL.0000031791.10922.CF","article-title":"Weight loss in early stage of Huntington\u2019s disease","volume":"59","author":"Djousse","year":"2002","journal-title":"Neurology"},{"issue":"Pt 4","key":"10.3233\/JHD-170273_ref46","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/brain\/awl027","article-title":"Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles","volume":"129","author":"Underwood","year":"2006","journal-title":"Brain"},{"issue":"3","key":"10.3233\/JHD-170273_ref47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-0404.1995.tb00438.x","article-title":"Decreased plasma alanine and isoleucine in Huntington\u2019s disease","volume":"91","author":"Reilmann","year":"1995","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.3233\/JHD-170273_ref48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archneurol.2010.358","article-title":"Validation of plasma branched chain amino acids as biomarkers in Huntington disease","volume":"68","author":"Mochel","year":"2011","journal-title":"Arch Neurol"},{"key":"10.3233\/JHD-170273_ref49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0447.1971.tb02141.x","article-title":"Serum levels of phenylalanine and tyrosine in Huntington\u2019s chorea","volume":"221","author":"Ottosson","year":"1971","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.3233\/JHD-170273_ref50","volume-title":"Amino acids in Huntington\u2019s chorea","author":"Ottosson","year":"1973"},{"issue":"7599","key":"10.3233\/JHD-170273_ref51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(69)92068-6","article-title":"Plasma-aminoacid levels in Huntington\u2019s chorea","volume":"1","author":"Perry","year":"1969","journal-title":"Lancet. 1"},{"key":"10.3233\/JHD-170273_ref52","volume-title":"Amino acids in plasma, cerebrospinal fluid, and brain of patients with Huntington\u2019s chorea","author":"Perry","year":"1973"},{"issue":"3","key":"10.3233\/JHD-170273_ref53","first-page":"311","article-title":"Plasma glucose, non-esterified fatty acids and amino acids in Huntington\u2019s chorea","volume":"52","author":"Phillipson","year":"1977","journal-title":"Clin Sci Mol Med"},{"issue":"1","key":"10.3233\/JHD-170273_ref54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0009-8981(73)90169-1","article-title":"Lysosomal enzymes, amino acids and acid metabolites of amines in Huntington\u2019s chorea","volume":"44","author":"Yates","year":"1973","journal-title":"Clin Chim Acta"},{"key":"10.3233\/JHD-170273_ref55","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jnutbio.2015.12.001","article-title":"Metabolic disturbances in plasma as biomarkers for Huntington\u2019s disease","volume":"31","author":"Cheng","year":"2016","journal-title":"J Nutr Biochem"},{"key":"10.3233\/JHD-170273_ref56","first-page":"7","article-title":"Cystathionine levels in patients with Huntington disease","author":"Aziz","year":"2015","journal-title":"PLoS Curr"},{"issue":"1","key":"10.3233\/JHD-170273_ref57","doi-asserted-by":"crossref","first-page":"e0146480","DOI":"10.1371\/journal.pone.0146480","article-title":"A metabolic study of Huntington\u2019s disease","volume":"11","author":"Nambron","year":"2016","journal-title":"PLoS One"},{"key":"10.3233\/JHD-170273_ref58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11306-016-1084-8","article-title":"Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington\u2019s disease peripheral blood samples","volume":"12","author":"Mastrokolias","year":"2016","journal-title":"Metabolomics"},{"issue":"Pt 11","key":"10.3233\/JHD-170273_ref59","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/brain\/awn212","article-title":"Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington\u2019s disease","volume":"131","author":"Leoni","year":"2008","journal-title":"Brain"},{"issue":"4","key":"10.3233\/JHD-170273_ref60","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archneur.65.4.476","article-title":"Glucose homeostasis in Huntington disease: Abnormalities in insulin sensitivity and early-phase insulin secretion","volume":"65","author":"Lalic","year":"2008","journal-title":"Arch Neurol"},{"issue":"5","key":"10.3233\/JHD-170273_ref61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jnnp.2010.208553","article-title":"Growth hormone response to arginine test differentiates between two subgroups of Huntington\u2019s disease patients","volume":"82","author":"Salvatore","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.3233\/JHD-170273_ref62","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/1354750X.2014.935955","article-title":"Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington\u2019s patients","volume":"19","author":"Ciancarelli","year":"2014","journal-title":"Biomarkers"},{"issue":"6","key":"10.3233\/JHD-170273_ref63","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00415-015-7753-0","article-title":"Fat-free mass and its predictors in Huntington\u2019s disease","volume":"262","author":"Sussmuth","year":"2015","journal-title":"J Neurol"},{"issue":"1","key":"10.3233\/JHD-170273_ref64","first-page":"47","article-title":"Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington\u2019s disease","volume":"30","author":"Ciancarelli","year":"2015","journal-title":"Funct Neurol"},{"issue":"3","key":"10.3233\/JHD-170273_ref65","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neulet.2011.03.025","article-title":"Whole body cholesterol metabolism is impaired in Huntington\u2019s disease","volume":"494","author":"Leoni","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.3233\/JHD-170273_ref66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2013.03.013","article-title":"Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression","volume":"55","author":"Leoni","year":"2013","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.3233\/JHD-170273_ref67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington\u2019s disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JHD-170273_ref68","first-page":"241","volume-title":"Cognitive impairments in Huntington\u2019s disease: Insights into the neuropsychology of the striatum","author":"Brandt","year":"1991"},{"issue":"2","key":"10.3233\/JHD-170273_ref69","first-page":"213","article-title":"Topography of cerebral atrophy in early Huntington\u2019s disease: A voxel based morphometric MRI study","volume":"75","author":"Kassubek","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.3233\/JHD-170273_ref70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00005072-199007000-00002","article-title":"Atrophy of the hypothalamic lateral tuberal nucleus in Huntington\u2019s disease","volume":"49","author":"Kremer","year":"1990","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.3233\/JHD-170273_ref71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0304-3940(91)90443-W","article-title":"The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington\u2019s disease","volume":"132","author":"Kremer","year":"1991","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.3233\/JHD-170273_ref72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/hmg\/ddi004","article-title":"Orexin loss in Huntington\u2019s disease","volume":"14","author":"Petersen","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.3233\/JHD-170273_ref73","first-page":"539","article-title":"Circadian rhythms of melatonin and cortisol in manifest Huntington\u2019s disease and in acute cortical ischemic stroke","volume":"68","author":"Adamczak-Ratajczak","year":"2017","journal-title":"J Physiol Pharmacol"},{"issue":"12","key":"10.3233\/JHD-170273_ref74","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00415-009-5196-1","article-title":"Delayed onset of the diurnal melatonin rise in patients with Huntington\u2019s disease","volume":"256","author":"Aziz","year":"2009","journal-title":"J Neurol"},{"issue":"12","key":"10.3233\/JHD-170273_ref75","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/mds.26003","article-title":"Plasma melatonin is reduced in Huntington\u2019s disease","volume":"29","author":"Kalliolia","year":"2014","journal-title":"Mov Disord"},{"issue":"4","key":"10.3233\/JHD-170273_ref76","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1210\/jc.2008-2543","article-title":"Increased hypothalamic-pituitary-adrenal axis activity in Huntington\u2019s disease","volume":"94","author":"Aziz","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.3233\/JHD-170273_ref77","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/hmg\/ddl094","article-title":"Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6\/2 transgenic mouse model of Huntington\u2019s disease","volume":"15","author":"Bjorkqvist","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.3233\/JHD-170273_ref78","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0006-3223(91)90007-9","article-title":"The limbic-hypothalamic-pituitary-adrenal axis in Huntington\u2019s disease","volume":"30","author":"Heuser","year":"1991","journal-title":"Biol Psychiatry"},{"issue":"8","key":"10.3233\/JHD-170273_ref79","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archneur.1988.00520320071018","article-title":"Cerebrospinal fluid correlates of depression in Huntington\u2019s disease","volume":"45","author":"Kurlan","year":"1988","journal-title":"Arch Neurol"},{"issue":"1","key":"10.3233\/JHD-170273_ref80","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0022-510X(95)00114-H","article-title":"Serum dehydroepiandrosterone and cortisol measurements in Huntington\u2019s chorea","volume":"132","author":"Leblhuber","year":"1995","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.3233\/JHD-170273_ref81","doi-asserted-by":"crossref","first-page":"e4962","DOI":"10.1371\/journal.pone.0004962","article-title":"Neuroendocrine disturbances in Huntington\u2019s disease","volume":"4","author":"Saleh","year":"2009","journal-title":"PLoS one"},{"issue":"3","key":"10.3233\/JHD-170273_ref82","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jne.12255","article-title":"Hypothalamic-pituitary-adrenal axis functioning in Huntington\u2019s disease and its association with depressive symptoms and suicidality","volume":"27","author":"Hubers","year":"2015","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"10.3233\/JHD-170273_ref83","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.brainresbull.2010.08.006","article-title":"Hypothalamic-pituitary-adrenal axis functioning in Huntington\u2019s disease mutation carriers compared with mutation-negative first-degree controls","volume":"83","author":"van Duijn","year":"2010","journal-title":"Brain Res Bull"},{"issue":"10","key":"10.3233\/JHD-170273_ref84","doi-asserted-by":"crossref","first-page":"e0138848","DOI":"10.1371\/journal.pone.0138848","article-title":"A 24-hour study of the hypothalamo-pituitary axes in Huntington\u2019s disease","volume":"10","author":"Kalliolia","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.3233\/JHD-170273_ref85","first-page":"199","article-title":"Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington\u2019s disease","volume":"28","author":"Markianos","year":"2007","journal-title":"Neuro Endocrinol Lett"},{"issue":"11","key":"10.3233\/JHD-170273_ref86","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.psyneuen.2012.10.020","article-title":"Cortisol and depression in pre-diagnosed and early stage Huntington\u2019s disease","volume":"38","author":"Shirbin","year":"2013","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"10.3233\/JHD-170273_ref87","first-page":"1051","article-title":"Neuroendocrine regulation in depression","volume":"33","author":"Carroll","year":"1976","journal-title":"II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry"},{"issue":"9","key":"10.3233\/JHD-170273_ref88","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/archpsyc.1985.01790320076010","article-title":"Cortisol secretion in endogenous depression","volume":"42","author":"Halbreich","year":"1985","journal-title":"I. Basal plasma levels. Arch Gen Psychiatry"},{"issue":"4","key":"10.3233\/JHD-170273_ref89","first-page":"328","article-title":"Neuroendocrine aspects of primary endogenous depression","volume":"44","author":"Rubin","year":"1987","journal-title":"I. Cortisol secretory dynamics in patients and matched controls. Arch Gen Psychiatry"},{"issue":"2","key":"10.3233\/JHD-170273_ref90","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0893-133X(00)00236-0","article-title":"Twenty-four-hour ACTH and cortisol pulsatility in depressed women","volume":"25","author":"Young","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.3233\/JHD-170273_ref91","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.psyneuen.2011.09.009","article-title":"Hair cortisol as a biological marker of chronic stress: Current status, future directions and unanswered questions","volume":"37","author":"Russell","year":"2012","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10.3233\/JHD-170273_ref92","first-page":"551","article-title":"Plasma growth hormone concentrations in Huntington\u2019s chorea","volume":"50","author":"Phillipson","year":"1976","journal-title":"Clin Sci Mol Med"},{"issue":"12","key":"10.3233\/JHD-170273_ref93","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/jnnp.46.12.1134","article-title":"Twenty-four hour plasma levels of growth hormone and prolactin in Huntington\u2019s disease","volume":"46","author":"Durso","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.3233\/JHD-170273_ref94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp.41.2.135","article-title":"Growth hormone and prolactin response to bromocriptine in patients with Huntington\u2019s chorea","volume":"41","author":"Chalmers","year":"1978","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.3233\/JHD-170273_ref95","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0024-3205(79)90357-6","article-title":"Growth hormone and prolactin secretion in Huntington\u2019s disease","volume":"24","author":"Levy","year":"1979","journal-title":"Life Sci"},{"issue":"3","key":"10.3233\/JHD-170273_ref96","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000115147","article-title":"Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson\u2019s disease and Huntington\u2019s chorea","volume":"19","author":"Murri","year":"1980","journal-title":"Eur Neurol"},{"issue":"4","key":"10.3233\/JHD-170273_ref97","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/eje.0.1510451","article-title":"Circulating and cerebrospinal fluid ghrelin and leptin: Potential role in altered body weight in Huntington\u2019s disease","volume":"151","author":"Popovic","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.3233\/JHD-170273_ref98","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","article-title":"Oxidative stress in Huntington\u2019s disease","volume":"9","author":"Browne","year":"1999","journal-title":"Brain Pathol"},{"issue":"5","key":"10.3233\/JHD-170273_ref99","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbadis.2011.11.014","article-title":"Antioxidants in Huntington\u2019s disease","volume":"1822","author":"Johri","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.3233\/JHD-170273_ref100","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.neuroscience.2006.10.056","article-title":"Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases","volume":"145","author":"Trushina","year":"2007","journal-title":"Neuroscience"},{"issue":"1","key":"10.3233\/JHD-170273_ref101","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1021\/tx700210j","article-title":"Oxidative stress and neurotoxicity","volume":"21","author":"Sayre","year":"2008","journal-title":"Chem Res Toxicol"},{"issue":"15","key":"10.3233\/JHD-170273_ref102","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1021\/jm200605a","article-title":"Important role of oxidative stress biomarkers in Huntington\u2019s disease","volume":"54","author":"Tunez","year":"2011","journal-title":"J Med Chem"},{"issue":"2","key":"10.3233\/JHD-170273_ref103","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2007.05.093","article-title":"Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington\u2019s disease patients","volume":"359","author":"Chen","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.3233\/JHD-170273_ref104","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00702-009-0364-0","article-title":"Oxidative stress and plasma aminopeptidase activity in Huntington\u2019s disease","volume":"117","author":"Duran","year":"2010","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"10.3233\/JHD-170273_ref105","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00415-007-0611-y","article-title":"Oxidative stress parameters in plasma of Huntington\u2019s disease patients, asymptomatic Huntington\u2019s disease gene carriers and healthy subjects: A cross-sectional study","volume":"254","author":"Klepac","year":"2007","journal-title":"J Neurol"},{"issue":"18","key":"10.3233\/JHD-170273_ref106","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.clinbiochem.2015.06.014","article-title":"Association of status redox with demographic, clinical and imaging parameters in patients with Huntington\u2019s disease","volume":"48","author":"Pena-Sanchez","year":"2015","journal-title":"Clin Biochem"},{"issue":"7","key":"10.3233\/JHD-170273_ref107","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/acn3.214","article-title":"A systems-level \u201cmisunderstanding\u201d: The plasma metabolome in Huntington\u2019s disease","volume":"2","author":"Rosas","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.3233\/JHD-170273_ref108","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","article-title":"Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington\u2019s disease","volume":"112","author":"Forrest","year":"2010","journal-title":"J Neurochem"},{"issue":"3","key":"10.3233\/JHD-170273_ref109","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.parkreldis.2008.05.012","article-title":"Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington\u2019s disease","volume":"15","author":"Constantinescu","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"10.3233\/JHD-170273_ref110","doi-asserted-by":"crossref","first-page":"e0163479","DOI":"10.1371\/journal.pone.0163479","article-title":"Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington\u2019s disease","volume":"11","author":"Rodrigues","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.3233\/JHD-170273_ref111","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1212\/NXI.0000000000000287","article-title":"Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease","volume":"3","author":"Vinther-Jensen","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.3233\/JHD-170273_ref112","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: A retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.3233\/JHD-170273_ref113","doi-asserted-by":"crossref","first-page":"e0172762","DOI":"10.1371\/journal.pone.0172762","article-title":"Tau or neurofilament light-Which is the more suitable biomarker for Huntington\u2019s disease?","volume":"12","author":"Niemela","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.3233\/JHD-170273_ref114","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J Clin Invest"},{"issue":"8","key":"10.3233\/JHD-170273_ref115","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1212\/WNL.0000000000005005","article-title":"Neurofilament light protein in blood predicts regional atrophy in Huntington disease","volume":"90","author":"Johnson","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.3233\/JHD-170273_ref116","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","article-title":"Increased levels of total tau protein in the cerebrospinal fluid in Huntington\u2019s disease","volume":"17","author":"Constantinescu","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.3233\/JHD-170273_ref117","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1074\/mcp.M800231-MCP200","article-title":"Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease","volume":"8","author":"Fang","year":"2009","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"10.3233\/JHD-170273_ref118","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","article-title":"Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease","volume":"139","author":"Rodrigues","year":"2016","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-170273_ref119","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1038\/srep12166","article-title":"Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression","volume":"5","author":"Southwell","year":"2015","journal-title":"Sci Rep"},{"issue":"4","key":"10.3233\/JHD-170273_ref122","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/pr200636x","article-title":"Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery","volume":"11","author":"Zhou","year":"2012","journal-title":"J Proteome Res"},{"key":"10.3233\/JHD-170273_ref123","doi-asserted-by":"crossref","unstructured":"Issaq HJ , Veenstra TD . Proteomic and metabolomic approaches to biomarker discovery. Academic Press; 2013.","DOI":"10.1016\/B978-0-12-394446-7.05001-9"},{"issue":"12","key":"10.3233\/JHD-170273_ref124","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1365-2362.2012.02727.x","article-title":"Better cancer biomarker discovery through better study design","volume":"42","author":"Rundle","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10.3233\/JHD-170273_ref125","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.3390\/s120708966","article-title":"Study designs and statistical analyses for biomarker research","volume":"12","author":"Gosho","year":"2012","journal-title":"Sensors"},{"key":"10.3233\/JHD-170273_ref126","first-page":"203","volume-title":"Biologic variation in health and illness: Race, age, and sex differences","author":"Overfield","year":"1995"},{"key":"10.3233\/JHD-170273_ref127","unstructured":"Fraser CG . Biological Variation: From Principles to Practice. Washington, DC AACC Press; 2001."},{"key":"10.3233\/JHD-170273_ref128","first-page":"97","article-title":"Circadian and sleep-dependent regulation of hormone release in humans","volume":"54","author":"Czeisler","year":"1999","journal-title":"Recent Prog Horm Res"},{"issue":"4","key":"10.3233\/JHD-170273_ref129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/09513599109028447","article-title":"The luteinizing hormone pulsatile secretion: Diurnal excursions in normally cycling and postmenopausal women","volume":"5","author":"Rossmanith","year":"1991","journal-title":"Gynecol Endocrinol"},{"key":"10.3233\/JHD-170273_ref130","unstructured":"Reed BG , Carr BR . The normal menstrual cycle and the control of ovulation. In: De GrootLJ, ChrousosG, DunganK, FeingoldKR, GrossmanA, HershmanJM, et al., editors. Endotext. South Dartmouth (MA);2000."},{"issue":"6","key":"10.3233\/JHD-170273_ref131","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/01.CIR.76.6.1224","article-title":"Seasonal cholesterol cycles: The Lipid Research Clinics Coronary Primary Prevention Trial placebo group","volume":"76","author":"Gordon","year":"1987","journal-title":"Circulation"},{"issue":"8","key":"10.3233\/JHD-170273_ref132","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.164.8.863","article-title":"Seasonal variation in serum cholesterol levels: Treatment implications and possible mechanisms","volume":"164","author":"Ockene","year":"2004","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.3233\/JHD-170273_ref133","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1079\/PNS19940063","article-title":"Seasonal variation in vitamin D","volume":"53","author":"Maxwell","year":"1994","journal-title":"Proc Nutr Soc"},{"key":"10.3233\/JHD-170273_ref134","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6823-9-16","article-title":"Salivary cortisol differs with age and sex and shows inverse associations with WHR in Swedish women: A cross-sectional study","volume":"9","author":"Larsson","year":"2009","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"10.3233\/JHD-170273_ref135","first-page":"2468","article-title":"Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol","volume":"81","author":"Van Cauter","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.3233\/JHD-170273_ref136","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1530\/eje.0.1350188","article-title":"Decrease in melatonin precedes follicle-stimulating hormone increase during perimenopause","volume":"135","author":"Vakkuri","year":"1996","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.3233\/JHD-170273_ref137","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jcem-68-1-53","article-title":"Serum luteinizing hormone concentrations increase 100-fold in females from 7 years to adulthood, as measured by time-resolved immunofluorometric assay","volume":"68","author":"Apter","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"issue":"5558","key":"10.3233\/JHD-170273_ref138","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/261333a0","article-title":"Plasma noradrenaline increases with age","volume":"261","author":"Ziegler","year":"1976","journal-title":"Nature"},{"issue":"4","key":"10.3233\/JHD-170273_ref139","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-079X.1986.tb00760.x","article-title":"Human melatonin production decreases with age","volume":"3","author":"Sack","year":"1986","journal-title":"J Pineal Res"},{"issue":"3","key":"10.3233\/JHD-170273_ref140","first-page":"238","article-title":"Age-related changes in the renin-aldosterone system","volume":"3","author":"Bauer","year":"1993","journal-title":"Physiological effects and clinical implications. Drugs Aging"},{"issue":"5","key":"10.3233\/JHD-170273_ref141","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ki.1975.120","article-title":"Effect on aging on plasma renin and aldosterone in normal man","volume":"8","author":"Weidmann","year":"1975","journal-title":"Kidney Int"},{"issue":"8","key":"10.3233\/JHD-170273_ref142","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/endo.138.8.5330","article-title":"Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1","volume":"138","author":"Sonntag","year":"1997","journal-title":"Endocrinology"},{"issue":"5337","key":"10.3233\/JHD-170273_ref143","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.278.5337.419","article-title":"The endocrinology of aging","volume":"278","author":"Lamberts","year":"1997","journal-title":"Science"},{"issue":"5999","key":"10.3233\/JHD-170273_ref144","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/bmj.4.5999.738","article-title":"Influence of age on serum prolactin levels in women and men","volume":"4","author":"Vekemans","year":"1975","journal-title":"Br Med J"},{"issue":"1","key":"10.3233\/JHD-170273_ref145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF00422886","article-title":"Urinary excretion of free noradrenaline and adrenaline related to age, sex and hypertension in 265 individuals","volume":"55","author":"Lehmann","year":"1986","journal-title":"Eur J Appl Physiol Occup Physiol"},{"issue":"3","key":"10.3233\/JHD-170273_ref146","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/BF00418345","article-title":"Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: The Hoorn Study","volume":"39","author":"Mooy","year":"1996","journal-title":"Diabetologia"},{"issue":"6","key":"10.3233\/JHD-170273_ref147","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1210\/edrv-16-6-686","article-title":"The aging thyroid","volume":"16","author":"Mariotti","year":"1995","journal-title":"Endocr Rev"},{"issue":"7","key":"10.3233\/JHD-170273_ref148","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1152\/physiolgenomics.00174.2013","article-title":"Identification of human exercise-induced myokines using secretome analysis","volume":"46","author":"Catoire","year":"2014","journal-title":"Physiol Genomics"},{"issue":"8041","key":"10.3233\/JHD-170273_ref149","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0140-6736(77)90272-0","article-title":"Prolactin control in Huntington\u2019s chorea","volume":"2","author":"Muller","year":"1977","journal-title":"Lancet"},{"issue":"10","key":"10.3233\/JHD-170273_ref150","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4088\/JCP.v61n1006","article-title":"Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses","volume":"61","author":"Melkersson","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.3233\/JHD-170273_ref151","doi-asserted-by":"crossref","first-page":"d6829","DOI":"10.1136\/bmj.d6829","article-title":"Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: Meta-epidemiology study","volume":"343","author":"Tzoulaki","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.3233\/JHD-170273_ref153","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.trsl.2011.08.005","article-title":"Patient-specific measures of a biomarker for the generation of individual reference intervals: Hemoglobin as example","volume":"158","author":"Sottas","year":"2011","journal-title":"Transl Res"},{"issue":"15-16","key":"10.3233\/JHD-170273_ref154","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cca.2012.04.010","article-title":"Biologic variability of C-reactive protein: Is the available information reliable?","volume":"413","author":"Braga","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.3233\/JHD-170273_ref155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2261-12-37","article-title":"Relationships between high-sensitive C-reactive protein and markers of arterial stiffness in hypertensive patients","volume":"12","author":"Gomez-Marcos","year":"2012","journal-title":"Differences by sex. BMC Cardiovasc Disord"},{"issue":"2","key":"10.3233\/JHD-170273_ref156","doi-asserted-by":"crossref","first-page":"e31112","DOI":"10.1371\/journal.pone.0031112","article-title":"Improved classification of Alzheimer\u2019s disease data via removal of nuisance variability","volume":"7","author":"Koikkalainen","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.3233\/JHD-170273_ref157","first-page":"79","article-title":"How to control confounding effects by statistical analysis","volume":"5","author":"Pourhoseingholi","year":"2012","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"3","key":"10.3233\/JHD-170273_ref158","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ki.5002650","article-title":"Confounding: What it is and how to deal with it","volume":"73","author":"Jager","year":"2008","journal-title":"Kidney Int"},{"issue":"3","key":"10.3233\/JHD-170273_ref159","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/00365513.2017.1295317","article-title":"Pre-analytical phase management: A review of the procedures from patient preparation to laboratory analysis","volume":"77","author":"Lima-Oliveira","year":"2017","journal-title":"Scand J Clin Lab Invest"},{"issue":"5","key":"10.3233\/JHD-170273_ref160","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jalz.2014.08.099","article-title":"Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer\u2019s disease research","volume":"11","author":"O\u2019Bryant","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.3233\/JHD-170273_ref161","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1468-1331.2009.02798.x","article-title":"Growth hormone and ghrelin secretion are associated with clinical severity in Huntington\u2019s disease","volume":"17","author":"Aziz","year":"2010","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.3233\/JHD-170273_ref162","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13547500701615017","article-title":"Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis","volume":"13","author":"Knudsen","year":"2008","journal-title":"Biomarkers"},{"issue":"10","key":"10.3233\/JHD-170273_ref163","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/07420528.2011.613683","article-title":"Diurnal variations of plasma homocysteine, total antioxidant status, and biological markers of muscle injury during repeated sprint: Effect on performance and muscle fatigue\u2013a pilot study","volume":"28","author":"Hammouda","year":"2011","journal-title":"Chronobiol Int"},{"issue":"1","key":"10.3233\/JHD-170273_ref164","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mce.2011.09.003","article-title":"Circadian system, sleep and endocrinology","volume":"349","author":"Morris","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.3233\/JHD-170273_ref165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2011.08.010","article-title":"Circadian clock signals in the adrenal cortex","volume":"349","author":"Ota","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"18","key":"10.3233\/JHD-170273_ref166","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.clinbiochem.2015.08.020","article-title":"The impact of time of sample collection on the measurement of thyroid stimulating hormone values in the serum","volume":"48","author":"Mirjanic-Azaric","year":"2015","journal-title":"Clin Biochem"},{"issue":"4","key":"10.3233\/JHD-170273_ref167","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1172\/JCI113450","article-title":"Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man","volume":"81","author":"Ho","year":"1988","journal-title":"J Clin Invest"},{"issue":"4","key":"10.3233\/JHD-170273_ref168","doi-asserted-by":"crossref","first-page":"865S","DOI":"10.1093\/ajcn\/78.4.865S","article-title":"Sugars, insulin sensitivity, and the postprandial state","volume":"78","author":"Daly","year":"2003","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.3233\/JHD-170273_ref169","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1159\/000112309","article-title":"A high glycemic meal suppresses the postprandial leptin response in normal healthy adults","volume":"51","author":"Barkoukis","year":"2007","journal-title":"Ann Nutr Metab"},{"issue":"5","key":"10.3233\/JHD-170273_ref170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MCO.0b013e32833cf3bc","article-title":"Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research","volume":"13","author":"Zhou","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"Suppl 1","key":"10.3233\/JHD-170273_ref171","first-page":"57","article-title":"Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids","volume":"37","author":"Grimble","year":"1998","journal-title":"Z Ernahrungswiss"},{"issue":"11","key":"10.3233\/JHD-170273_ref172","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.metabol.2009.05.011","article-title":"Sex differences in postprandial plasma tumor necrosis factor-alpha, interleukin-6, and C-reactive protein concentrations","volume":"58","author":"Payette","year":"2009","journal-title":"Metabolism"},{"issue":"16","key":"10.3233\/JHD-170273_ref173","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/01.CIR.0000034509.14906.AE","article-title":"Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress","volume":"106","author":"Esposito","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.3233\/JHD-170273_ref174","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/01.CIR.0000074221.68903.77","article-title":"Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers","volume":"108","author":"Carroll","year":"2003","journal-title":"Circulation"},{"issue":"1-2","key":"10.3233\/JHD-170273_ref175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clinbiochem.2013.11.002","article-title":"Influence of diet and sample collection time on 77 laboratory tests on healthy adults","volume":"47","author":"Plumelle","year":"2014","journal-title":"Clin Biochem"},{"issue":"17","key":"10.3233\/JHD-170273_ref176","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1021\/ac2012224","article-title":"Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer","volume":"83","author":"Wedge","year":"2011","journal-title":"Anal Chem"},{"issue":"2","key":"10.3233\/JHD-170273_ref177","doi-asserted-by":"crossref","first-page":"e89728","DOI":"10.1371\/journal.pone.0089728","article-title":"Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples","volume":"9","author":"Breier","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.3233\/JHD-170273_ref178","doi-asserted-by":"crossref","first-page":"e21230","DOI":"10.1371\/journal.pone.0021230","article-title":"Differences between human plasma and serum metabolite profiles","volume":"6","author":"Yu","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.3233\/JHD-170273_ref179","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1021\/pr800396c","article-title":"Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides","volume":"7","author":"Yi","year":"2008","journal-title":"J Proteome Res"},{"issue":"6","key":"10.3233\/JHD-170273_ref180","first-page":"685","article-title":"Thrombin induces broad spectrum proteolysis in human serum samples","volume":"47","author":"O\u2019Mullan","year":"2009","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.3233\/JHD-170273_ref181","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0009-9120(01)00196-5","article-title":"Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones","volume":"34","author":"Evans","year":"2001","journal-title":"Clin Biochem"},{"issue":"1","key":"10.3233\/JHD-170273_ref182","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6890-2-2","article-title":"Effects of EDTA and Sodium Citrate on hormone measurements by fluorometric (FIA) and immunofluorometric (IFMA) methods","volume":"2","author":"Kohek","year":"2002","journal-title":"BMC Clin Pathol"},{"issue":"3","key":"10.3233\/JHD-170273_ref183","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1021\/ac102806p","article-title":"Characterization of differences between blood sample matrices in untargeted metabolomics","volume":"83","author":"Denery","year":"2011","journal-title":"Anal Chem"},{"issue":"2","key":"10.3233\/JHD-170273_ref184","doi-asserted-by":"crossref","first-page":"202","DOI":"10.11613\/BM.2012.023","article-title":"Stability studies of common biochemical analytes in serum separator tubes with or without gel barrier subjected to various storage conditions","volume":"22","author":"Cuhadar","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"issue":"1-2","key":"10.3233\/JHD-170273_ref185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clinbiochem.2009.10.001","article-title":"Impact of blood collection devices on clinical chemistry assays","volume":"43","author":"Bowen","year":"2010","journal-title":"Clin Biochem"},{"issue":"8","key":"10.3233\/JHD-170273_ref186","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4155\/bio.15.16","article-title":"The influence of sample collection methodology and sample preprocessing on the blood metabolic profile","volume":"7","author":"Jorgenrud","year":"2015","journal-title":"Bioanalysis"},{"issue":"1","key":"10.3233\/JHD-170273_ref187","doi-asserted-by":"crossref","first-page":"31","DOI":"10.11613\/BM.2014.006","article-title":"Interferences from blood collection tube components on clinical chemistry assays","volume":"24","author":"Bowen","year":"2014","journal-title":"Biochem Med (Zagreb)"},{"issue":"2","key":"10.3233\/JHD-170273_ref188","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1309\/3WM7XJ7RD8BCLNKX","article-title":"Effects of storage time and exogenous protease inhibitors on plasma protein levels","volume":"126","author":"Ayache","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.3233\/JHD-170273_ref189","doi-asserted-by":"crossref","first-page":"e22966","DOI":"10.1371\/journal.pone.0022966","article-title":"Brain-derived neurotrophic factor in patients with Huntington\u2019s disease","volume":"6","author":"Zuccato","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JHD-170273_ref190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cyto.2016.05.010","article-title":"Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions","volume":"84","author":"Aziz","year":"2016","journal-title":"Cytokine"},{"issue":"3","key":"10.3233\/JHD-170273_ref191","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1208\/s12248-014-9573-z","article-title":"Stability: Recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team","volume":"16","author":"van de Merbel","year":"2014","journal-title":"AAPS J"},{"issue":"1-3","key":"10.3233\/JHD-170273_ref192","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.brainresbull.2007.03.009","article-title":"Measurements of brain-derived neurotrophic factor: Methodological aspects and demographical data","volume":"73","author":"Trajkovska","year":"2007","journal-title":"Brain Res Bull"},{"issue":"1","key":"10.3233\/JHD-170273_ref193","doi-asserted-by":"crossref","first-page":"70","DOI":"10.11613\/BM.2013.009","article-title":"The effect of storage time and freeze-thaw cycles on the stability of serum samples","volume":"23","author":"Cuhadar","year":"2013","journal-title":"Biochem Med (Zagreb)"},{"issue":"8","key":"10.3233\/JHD-170273_ref194","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4155\/bio-2017-0009","article-title":"Recommendations for clinical biomarker specimen preservation and stability assessments","volume":"9","author":"Dakappagari","year":"2017","journal-title":"Bioanalysis"},{"issue":"3","key":"10.3233\/JHD-170273_ref195","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3892\/mmr.2013.1263","article-title":"Clinical evaluation of the levels of 12 cytokines in serum\/plasma under various storage conditions using evidence biochip arrays","volume":"7","author":"Guo","year":"2013","journal-title":"Mol Med Rep"},{"key":"10.3233\/JHD-170273_ref196","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fneur.2015.00153","article-title":"Chasing the effects of pre-analytical confounders - a multicenter study on CSF-AD biomarkers","volume":"6","author":"Leitao","year":"2015","journal-title":"Front Neurol"},{"issue":"7","key":"10.3233\/JHD-170273_ref197","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1373\/clinchem.2014.228783","article-title":"Preanalytical variables affecting the integrity of human biospecimens in biobanking","volume":"61","author":"Ellervik","year":"2015","journal-title":"Clin Chem"},{"issue":"1","key":"10.3233\/JHD-170273_ref198","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/pr800545q","article-title":"Standard operating procedures for serum and plasma collection: Early detection research network consensus statement standard operating procedure integration working group","volume":"8","author":"Tuck","year":"2009","journal-title":"J Proteome Res"},{"issue":"4","key":"10.3233\/JHD-170273_ref199","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0037-1613072","article-title":"Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation","volume":"87","author":"Fujimura","year":"2002","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.3233\/JHD-170273_ref200","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2007.11.019","article-title":"Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects","volume":"431","author":"Tang","year":"2008","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.3233\/JHD-170273_ref201","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.pnpbp.2007.11.011","article-title":"Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?","volume":"32","author":"Mitoma","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.3233\/JHD-170273_ref202","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neurobiolaging.2004.03.002","article-title":"The impact of age, weight and gender on BDNF levels in human platelets and plasma","volume":"26","author":"Lommatzsch","year":"2005","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.3233\/JHD-170273_ref203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.psyneuen.2010.07.013","article-title":"Determinants of serum brain-derived neurotrophic factor","volume":"36","author":"Bus","year":"2011","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.3233\/JHD-170273_ref204","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000358061","article-title":"Preanalysis storage conditions influence the measurement of brain-derived neurotrophic factor levels in peripheral blood","volume":"69","author":"Tsuchimine","year":"2014","journal-title":"Neuropsychobiology"},{"issue":"9","key":"10.3233\/JHD-170273_ref205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JHD-170273_ref208","first-page":"1","article-title":"Proteome-wide post-translational modification statistics: Frequency analysis and curation of the swiss-prot database","author":"Khoury","year":"2011","journal-title":"Sci Rep"},{"issue":"3","key":"10.3233\/JHD-170273_ref209","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF biomarker variability in the Alzheimer\u2019s Association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"19","key":"10.3233\/JHD-170273_ref210","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1158\/1078-0432.CCR-07-4535","article-title":"Validation of analytic methods for biomarkers used in drug development","volume":"14","author":"Chau","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3233\/JHD-170273_ref211","first-page":"6","article-title":"A practical guide to immunoassay method validation","author":"Andreasson","year":"2015","journal-title":"Front Neurol"},{"issue":"6","key":"10.3233\/JHD-170273_ref212","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1179\/acb.2006.053","article-title":"Variability among five different commercial IGF-1 immunoassays in conditions of childhood-onset GH deficiency and GH therapy","volume":"61","author":"Anckaert","year":"2006","journal-title":"Acta Clin Belg"},{"issue":"4","key":"10.3233\/JHD-170273_ref213","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1309\/AJCPU2SKW1TFKSWY","article-title":"Analytical variability among methods for the measurement of 25-hydroxyvitamin D: Still adding to the noise","volume":"140","author":"Holmes","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.3233\/JHD-170273_ref215","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fneur.2015.00179","article-title":"A practical guide to immunoassay method validation","volume":"6","author":"Andreasson","year":"2015","journal-title":"Front Neurol"},{"issue":"19","key":"10.3233\/JHD-170273_ref216","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1158\/1078-0432.CCR-07-4535","article-title":"Validation of analytic methods for biomarkers used in drug development","volume":"14","author":"Chau","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6060","key":"10.3233\/JHD-170273_ref217","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1126\/science.1211811","article-title":"Improving validation practices in \u201comics\u201d research","volume":"334","author":"Ioannidis","year":"2011","journal-title":"Science"},{"issue":"9","key":"10.3233\/JHD-170273_ref218","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.15252\/embr.201744876","article-title":"The reproducibility \u201ccrisis\u201d: Reaction to replication crisis should not stifle innovation","volume":"18","author":"Hunter","year":"2017","journal-title":"EMBO Rep"},{"issue":"6","key":"10.3233\/JHD-170273_ref219","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2217\/bmm.12.84","article-title":"8-OHdG: Its (limited) potential as a biomarker for Huntington\u2019s disease","volume":"6","author":"Killoran","year":"2012","journal-title":"Biomark Med"},{"issue":"2","key":"10.3233\/JHD-170273_ref220","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"issue":"3","key":"10.3233\/JHD-170273_ref221","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.nbd.2012.02.012","article-title":"8OHdG as a marker for Huntington disease progression","volume":"46","author":"Long","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.3233\/JHD-170273_ref222","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archneur.63.6.883","article-title":"Preparing for preventive clinical trials: The Predict-HD study","volume":"63","author":"Paulsen","year":"2006","journal-title":"Arch Neurol"},{"issue":"21","key":"10.3233\/JHD-170273_ref223","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1212\/WNL.0b013e318293e1a1","article-title":"8OHdG is not a biomarker for Huntington disease state or progression","volume":"80","author":"Borowsky","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JHD-170273_ref224","first-page":"221","article-title":"Redox balance signalling in occupational stress: Modification by nutraceutical intervention","volume":"25","author":"Marotta","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"issue":"1","key":"10.3233\/JHD-170273_ref225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.psy.0000195780.37277.2a","article-title":"Increased serum levels of 8-hydroxy-2\u2019-deoxyguanosine in clinical depression","volume":"68","author":"Forlenza","year":"2006","journal-title":"Psychosom Med"},{"issue":"3","key":"10.3233\/JHD-170273_ref226","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1055-9965.EPI-05-0658","article-title":"Leanness, smoking, and enhanced oxidative DNA damage","volume":"15","author":"Mizoue","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.3233\/JHD-170273_ref227","doi-asserted-by":"crossref","first-page":"e37412","DOI":"10.1371\/journal.pone.0037412","article-title":"Traffic-related air pollution and DNA damage: A longitudinal study in Taiwanese traffic conductors","volume":"7","author":"Huang","year":"2012","journal-title":"PloS one"},{"issue":"7","key":"10.3233\/JHD-170273_ref228","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/mnfr.201100676","article-title":"Polyphenol-rich foods exhibit DNA antioxidative properties and protect the glutathione system in healthy subjects","volume":"56","author":"Pedret","year":"2012","journal-title":"Mol Nutr Food Res"},{"key":"10.3233\/JHD-170273_ref229","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1749-6632.2002.tb02912.x","article-title":"Wine, diet, antioxidant defenses, and oxidative damage","volume":"957","author":"Perez","year":"2002","journal-title":"Ann N Y Acad Sci"},{"issue":"7404","key":"10.3233\/JHD-170273_ref230","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/bmj.326.7404.1453","article-title":"Effect of interpretive bias on research evidence","volume":"326","author":"Kaptchuk","year":"2003","journal-title":"BMJ"},{"issue":"7","key":"10.3233\/JHD-170273_ref231","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jclinepi.2013.11.011","article-title":"Blinded interpretation of study results can feasibly and effectively diminish interpretation bias","volume":"67","author":"Jarvinen","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"7259","key":"10.3233\/JHD-170273_ref232","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bmj.321.7259.504","article-title":"Statistics Notes - Blinding in clinical trials and other studies","volume":"321","author":"Day","year":"2000","journal-title":"Brit Med J"},{"issue":"3","key":"10.3233\/JHD-170273_ref233","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12035-013-8590-8","article-title":"New insight into neurodegeneration: The role of proteomics","volume":"49","author":"Pal","year":"2014","journal-title":"Mol Neurobiol"},{"issue":"7","key":"10.3233\/JHD-170273_ref234","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/NEN.0000000000000091","article-title":"Metabolomics of human brain aging and age-related neurodegenerative diseases","volume":"73","author":"Jove","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.3233\/JHD-170273_ref235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bfgp\/elr003","article-title":"Functional and systems biology approaches to Huntington\u2019s disease","volume":"10","author":"Gonzalez-Couto","year":"2011","journal-title":"Brief Funct Genomics"},{"key":"10.3233\/JHD-170273_ref236","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-1-4939-3816-2_10","article-title":"Role of systems biology in brain injury biomarker discovery: Neuroproteomics application","volume":"1462","author":"Jaber","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"12","key":"10.3233\/JHD-170273_ref237","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/bioinformatics\/btu111","article-title":"BioPlat: A software for human cancer biomarker discovery","volume":"30","author":"Butti","year":"2014","journal-title":"Bioinformatics"},{"key":"10.3233\/JHD-170273_ref238","doi-asserted-by":"crossref","unstructured":"Lin Y , Qian F , Shen L , Chen F , Chen J , Shen B . Computer-aided biomarker discovery for precision medicine: Data resources, models and applications. Brief Bioinform. 2017. doi: 10.1093\/bib\/bbx158","DOI":"10.1093\/bib\/bbx158"},{"issue":"5","key":"10.3233\/JHD-170273_ref239","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ddr.21213","article-title":"Application of chemometric techniques in search of clinically applicable biomarkers of disease","volume":"75","author":"Kotlowska","year":"2014","journal-title":"Drug Dev Res"},{"issue":"13","key":"10.3233\/JHD-170273_ref240","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1089\/neu.2012.2631","article-title":"Systems biology approaches for discovering biomarkers for traumatic brain injury","volume":"30","author":"Feala","year":"2013","journal-title":"J Neurotrauma"},{"issue":"8","key":"10.3233\/JHD-170273_ref241","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/pmic.201400391","article-title":"Workflows for automated downstream data analysis and visualization in large-scale computational mass spectrometry","volume":"15","author":"Aiche","year":"2015","journal-title":"Proteomics"},{"issue":"W1","key":"10.3233\/JHD-170273_ref242","doi-asserted-by":"crossref","first-page":"W251","DOI":"10.1093\/nar\/gkv380","article-title":"MetaboAnalyst 3.0\u2013making metabolomics more meaningful","volume":"43","author":"Xia","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.3233\/JHD-170273_ref243","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nmeth.4260","article-title":"Systems biology guided by XCMS Online metabolomics","volume":"14","author":"Huan","year":"2017","journal-title":"Nat Methods"},{"issue":"2","key":"10.3233\/JHD-170273_ref244","doi-asserted-by":"crossref","first-page":"e88854","DOI":"10.1371\/journal.pone.0088854","article-title":"A systematic review of biomarkers for disease progression in Alzheimer\u2019s disease","volume":"9","author":"McGhee","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.3233\/JHD-170273_ref245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.dadm.2015.09.001","article-title":"Revolutionizing Alzheimer\u2019s disease and clinical trials through biomarkers","volume":"1","author":"Mattsson","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"issue":"8","key":"10.3233\/JHD-170273_ref246","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington\u2019s disease decades before diagnosis: The Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.3233\/JHD-170273_ref247","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/01.wnl.0000237331.16541.ac","article-title":"Evidence of publication bias in reporting acute stroke clinical trials","volume":"67","author":"Liebeskind","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"10.3233\/JHD-170273_ref248","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Med"},{"issue":"7003","key":"10.3233\/JHD-170273_ref249","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.311.7003.485","article-title":"Absence of evidence is not evidence of absence","volume":"311","author":"Altman","year":"1995","journal-title":"BMJ"},{"issue":"8","key":"10.3233\/JHD-170273_ref250","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1371\/journal.pone.0003081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias","volume":"3","author":"Dwan","year":"2008","journal-title":"PLoS One"},{"issue":"11","key":"10.3233\/JHD-170273_ref251","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archpedi.159.11.1036","article-title":"Negative results and impact factor: A lesson from neonatology","volume":"159","author":"Littner","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"10.3233\/JHD-170273_ref252","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jclinpath-2015-203384","article-title":"Quality assessment and preservation of RNA from biobank tissue specimens: A systematic review","volume":"69","author":"Caixeiro","year":"2016","journal-title":"J Clin Pathol"},{"issue":"10","key":"10.3233\/JHD-170273_ref253","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrneurol.2015.173","article-title":"Body fluid biomarkers for multiple sclerosis\u2013the long road to clinical application","volume":"11","author":"Teunissen","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"13","key":"10.3233\/JHD-170273_ref254","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1352458513488232","article-title":"Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis","volume":"19","author":"Teunissen","year":"2013","journal-title":"Mult Scler"},{"issue":"13","key":"10.3233\/JHD-170273_ref255","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/WNL.0000000000000809","article-title":"Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders","volume":"83","author":"Gnanapavan","year":"2014","journal-title":"Neurology"},{"issue":"4-5","key":"10.3233\/JHD-170273_ref256","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clinbiochem.2013.12.024","article-title":"Biobanking of CSF: International standardization to optimize biomarker development","volume":"47","author":"Teunissen","year":"2014","journal-title":"Clin Biochem"},{"issue":"4","key":"10.3233\/JHD-170273_ref257","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: An update","volume":"6","author":"del Campo","year":"2012","journal-title":"Biomark Med"},{"issue":"1","key":"10.3233\/JHD-170273_ref258","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","article-title":"Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: A consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative","volume":"8","author":"Vanderstichele","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"22","key":"10.3233\/JHD-170273_ref259","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","article-title":"A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking","volume":"73","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-170273_ref262","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/bio.2018.0001","article-title":"The Revision of the ISBER Best Practices: Summary of Changes and the Editorial Team\u2019s Development Process","volume":"16","author":"Campbell","year":"2018","journal-title":"Biopreserv Biobank"},{"issue":"1","key":"10.3233\/JHD-170273_ref263","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JAD-160573","article-title":"Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: A view of the regulatory science qualification landscape from the Coalition Against Major Diseases CSF Biomarker Team","volume":"55","author":"Arneric","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JHD-170273_ref264","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-1872-0_15","article-title":"The European Medicines Agency experience with biomarker qualification","volume":"1243","author":"Manolis","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.3233\/JHD-170273_ref265","doi-asserted-by":"crossref","unstructured":"Leptak C , Menetski JP , Wagner JA , Aubrecht J , Brady L , Brumfield M , et al. What evidence do we need for biomarker qualification? Sci Transl Med. 2017;9(417).","DOI":"10.1126\/scitranslmed.aal4599"},{"issue":"6","key":"10.3233\/JHD-170273_ref268","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/JHD-170273_ref269","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.3233\/JHD-170273_ref270","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.3233\/JHD-170273_ref271","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.3233\/JHD-170273_ref272","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/joim.12199","article-title":"Harmonized diagnostic criteria for Alzheimer\u2019s disease: Recommendations","volume":"275","author":"Morris","year":"2014","journal-title":"J Intern Med"},{"issue":"11-12","key":"10.3233\/JHD-170273_ref273","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/prca.201400067","article-title":"The untapped potential of proteomic analysis in pediatric pulmonary hypertension","volume":"8","author":"Nies","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"10.3233\/JHD-170273_ref274","first-page":"950","article-title":"Increased levels of hemoglobin and alpha1-microglobulin in Huntington\u2019s disease","volume":"4","author":"Olsson","year":"2012","journal-title":"Front Biosci (Elite Ed)"},{"issue":"3","key":"10.3233\/JHD-170273_ref275","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archpsyc.1980.01780160095011","article-title":"Blood monoamine metabolism in Huntington\u2019s disease","volume":"37","author":"Belendiuk","year":"1980","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.3233\/JHD-170273_ref276","doi-asserted-by":"crossref","first-page":"e15809","DOI":"10.1371\/journal.pone.0015809","article-title":"Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington\u2019s disease","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.3233\/JHD-170273_ref277","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ymgme.2007.10.002","article-title":"Low plasma total cholesterol in patients with Huntington\u2019s disease and first-degree relatives","volume":"93","author":"Markianos","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.3233\/JHD-170273_ref278","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jns.2016.02.018","article-title":"Liver function in Huntington\u2019s disease assessed by blood biochemical analyses in a clinical setting","volume":"362","author":"Nielsen","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.3233\/JHD-170273_ref279","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-017-0845-3"},{"issue":"5","key":"10.3233\/JHD-170273_ref280","doi-asserted-by":"crossref","first-page":"e0127654","DOI":"10.1371\/journal.pone.0127654","article-title":"High protein diet and Huntington\u2019s disease","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.3233\/JHD-170273_ref281","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/hmg\/ddl481","article-title":"Dysregulation of C\/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington\u2019s disease","volume":"16","author":"Chiang","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.3233\/JHD-170273_ref282","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00343834","article-title":"Huntington\u2019s disease - imbalance of free amino acids in the cerebrospinal fluid of patients and offspring at-risk","volume":"231","author":"Oepen","year":"1982","journal-title":"Arch Psychiatr Nervenkr"},{"issue":"13","key":"10.3233\/JHD-170273_ref283","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0024-3205(80)90244-1","article-title":"Cerebrospinal fluid homocarnosine in Huntington\u2019s disease","volume":"26","author":"Bohlen","year":"1980","journal-title":"Life Sci"},{"issue":"5","key":"10.3233\/JHD-170273_ref284","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s11064-008-9851-1","article-title":"Plasma homovanillic acid and prolactin in Huntington\u2019s disease","volume":"34","author":"Markianos","year":"2009","journal-title":"Neurochem Res"},{"issue":"3","key":"10.3233\/JHD-170273_ref285","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/jnnp.44.3.258","article-title":"Homovanilic acid in Huntington\u2019s disease and Sydenham\u2019s chorea","volume":"44","author":"Cunha","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.3233\/JHD-170273_ref286","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-199502000-00007","article-title":"Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington\u2019s disease","volume":"18","author":"Garcia Ruiz","year":"1995","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.3233\/JHD-170273_ref287","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1471-4159.1992.tb09283.x","article-title":"Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington\u2019s disease: Evidence for an overactive dopaminergic brain transmission","volume":"58","author":"Garrett","year":"1992","journal-title":"J Neurochem"},{"issue":"1","key":"10.3233\/JHD-170273_ref288","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0022-510X(94)90134-1","article-title":"Huntington\u2019s disease: The neuroexcitotoxin aspartate is increased in platelets and decreased in plasma","volume":"127","author":"Reilmann","year":"1994","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.3233\/JHD-170273_ref289","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","article-title":"Energy metabolism defects in Huntington\u2019s disease and effects of coenzyme Q10","volume":"41","author":"Koroshetz","year":"1997","journal-title":"Ann Neurol"},{"issue":"3","key":"10.3233\/JHD-170273_ref290","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-012-6732-y","article-title":"The relationship between cortisol and verbal memory in the early stages of Huntington\u2019s disease","volume":"260","author":"Shirbin","year":"2013","journal-title":"J Neurol"},{"issue":"3","key":"10.3233\/JHD-170273_ref291","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0022-510X(89)90120-2","article-title":"Endocrine functions in Huntington\u2019s disease. A two-and-a-half years follow-up study","volume":"90","author":"Kremer","year":"1989","journal-title":"J Neurol Sci"},{"issue":"9","key":"10.3233\/JHD-170273_ref292","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.33.9.1299","article-title":"Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington\u2019s disease","volume":"33","author":"Durso","year":"1983","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-170273_ref293","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000212174","article-title":"Abnormal glucose tolerance and arginine tolerance tests in Huntington\u2019s disease","volume":"23","author":"Podolsky","year":"1977","journal-title":"Gerontology"},{"issue":"1","key":"10.3233\/JHD-170273_ref294","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1210\/jcem-41-1-160","article-title":"Exaggerated growth hormone response to arginine infusion in Huntington\u2019s disease","volume":"41","author":"Leopold","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.3233\/JHD-170273_ref295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0b013e3181e62076","article-title":"High insulinlike growth factor I is associated with cognitive decline in Huntington disease","volume":"75","author":"Saleh","year":"2010","journal-title":"Neurology"},{"issue":"9","key":"10.3233\/JHD-170273_ref296","doi-asserted-by":"crossref","first-page":"e0162890","DOI":"10.1371\/journal.pone.0162890","article-title":"Insulin-like growth factor-1 but not insulin predicts cognitive decline in Huntington\u2019s disease","volume":"11","author":"Salem","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.3233\/JHD-170273_ref297","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2265.2009.03661.x","article-title":"Leptin secretion rate increases with higher CAG repeat number in Huntington\u2019s disease patients","volume":"73","author":"Aziz","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.3233\/JHD-170273_ref298","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/ene.12750","article-title":"Ubiquit A potential cerebrospinal fluid progression marker in Huntington\u2019s disease","volume":"22","author":"Vinther-Jensen","year":"2015","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.3233\/JHD-170273_ref299","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0304-3940(91)90711-2","article-title":"Serum ferritin deficiency in Huntington\u2019s disease patients","volume":"129","author":"Bonilla","year":"1991","journal-title":"Neurosci Lett"},{"issue":"5","key":"10.3233\/JHD-170273_ref300","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF02943258","article-title":"Serum iron, total iron binding capacity and ferritin in early Huntington disease patients","volume":"163","author":"Morrison","year":"1994","journal-title":"Ir J Med Sci"},{"issue":"Pt 5","key":"10.3233\/JHD-170273_ref301","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"issue":"4","key":"10.3233\/JHD-170273_ref302","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington\u2019s disease striatum: Evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J Neurochem"},{"issue":"11","key":"10.3233\/JHD-170273_ref303","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/archneur.1978.00500350032006","article-title":"Huntington\u2019s disease. Cerebrospinal fluid GABA levels in at-risk individuals","volume":"35","author":"Manyam","year":"1978","journal-title":"Arch Neurol"},{"issue":"1-2","key":"10.3233\/JHD-170273_ref304","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0006-8993(84)90475-X","article-title":"Free and conjugated GABA in human cerebrospinal fluid: Effect of degenerative neurologic diseases and isoniazid","volume":"307","author":"Manyam","year":"1984","journal-title":"Brain Res"},{"issue":"11","key":"10.3233\/JHD-170273_ref305","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archneur.1977.00500230053008","article-title":"Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders","volume":"34","author":"Enna","year":"1977","journal-title":"Arch Neurol"},{"issue":"1-2","key":"10.3233\/JHD-170273_ref306","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0304-3940(93)90168-K","article-title":"CSF and serum metabolic profile of patients with Huntington\u2019s chorea: A study by high resolution proton NMR spectroscopy and HPLC","volume":"154","author":"Nicoli","year":"1993","journal-title":"Neurosci Lett"},{"issue":"8","key":"10.3233\/JHD-170273_ref307","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.26.8.777","article-title":"Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease","volume":"26","author":"Achar","year":"1976","journal-title":"Neurology"},{"issue":"1-2","key":"10.3233\/JHD-170273_ref308","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2011.12.014","article-title":"NGF and nitrosative stress in patients with Huntington\u2019s disease","volume":"315","author":"Tasset","year":"2012","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.3233\/JHD-170273_ref309","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jnr.490320305","article-title":"Two-site enzyme immunoassay for beta NGF applied to human patient sera","volume":"32","author":"Lorigados","year":"1992","journal-title":"J Neurosci Res"},{"issue":"11","key":"10.3233\/JHD-170273_ref310","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.bbadis.2016.08.019","article-title":"An impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington\u2019s disease related cardiomyopathy","volume":"1862","author":"Toczek","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JHD-170273_ref311","first-page":"233","article-title":"Phosphorus-31 magnetic resonance studies on blood in Huntington\u2019s disease","volume":"104","author":"Pettegrew","year":"1979","journal-title":"Trans Am Neurol Assoc"},{"issue":"4","key":"10.3233\/JHD-170273_ref312","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.20428","article-title":"Plasma testosterone in male patients with Huntington\u2019s disease: Relations to severity of illness and dementia","volume":"57","author":"Markianos","year":"2005","journal-title":"Ann Neurol"},{"issue":"9","key":"10.3233\/JHD-170273_ref313","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2826.2009.01898.x","article-title":"Huntington\u2019s disease does not appear to increase the risk of diabetes mellitus","volume":"21","author":"Boesgaard","year":"2009","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"10.3233\/JHD-170273_ref314","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/WNL.40.1.20","article-title":"What excitotoxin kills striatal neurons in Huntington\u2019s disease? Clues from neurochemical studies","volume":"40","author":"Perry","year":"1990","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/JHD-170273_ref315","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2265.2010.03836.x","article-title":"Altered thyrotropic and lactotropic axes regulation in Huntington\u2019s disease","volume":"73","author":"Aziz","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.3233\/JHD-170273_ref316","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.22907","article-title":"The relationship between uric acid levels and Huntington\u2019s disease progression","volume":"25","author":"Auinger","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-170273_ref317","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00429695","article-title":"Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders","volume":"63","author":"Davis","year":"1979","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.3233\/JHD-170273_ref318","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00314742","article-title":"Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington\u2019s disease","volume":"237","author":"Manyam","year":"1990","journal-title":"J Neurol"},{"issue":"9","key":"10.3233\/JHD-170273_ref319","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s00415-006-0146-7","article-title":"Hypocretin-1 (orexin A) levels are normal in Huntington\u2019s disease","volume":"253","author":"Baumann","year":"2006","journal-title":"J Neurol"},{"issue":"1","key":"10.3233\/JHD-170273_ref320","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1399-0004.2006.00636.x","article-title":"Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease","volume":"70","author":"Bjorkqvist","year":"2006","journal-title":"Clin Genet"},{"issue":"12","key":"10.3233\/JHD-170273_ref321","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/sleep\/28.12.1607","article-title":"CSF hypocretin levels are normal in Huntington\u2019s disease patients","volume":"28","author":"Gaus","year":"2005","journal-title":"Sleep"},{"issue":"4","key":"10.3233\/JHD-170273_ref322","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1750-3639.2008.00135.x","article-title":"Hypocretin and melanin-concentrating hormone in patients with Huntington disease","volume":"18","author":"Aziz","year":"2008","journal-title":"Brain Pathol"},{"issue":"2","key":"10.3233\/JHD-170273_ref323","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0304-3940(91)90874-S","article-title":"Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington\u2019s disease","volume":"122","author":"Heyes","year":"1991","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.3233\/JHD-170273_ref324","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.410240417","article-title":"Cerebrospinal fluid levels of quinolinic acid in Huntington\u2019s disease and schizophrenia","volume":"24","author":"Schwarcz","year":"1988","journal-title":"Ann Neurol"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-170273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:24Z","timestamp":1777453044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-170273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":312,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jhd-170273","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}